Turing Pharmaceuticals' CEO, Martin Shkreli—formerly a hedge-fund manager and often referred to as "Pharma Bro"—acquired Daraprim (pyrimethamine), a medication used to treat toxoplasmosis, from Impax Laboratories in August for $55 million. Following the acquisition, he raised the drug's price by an astonishing 5000%.

Originally approved by the Food and Drug Administration in 1953, GlaxoSmithKline marketed Daraprim for approximately $1 per tablet. In 2010, CorePharma purchased GlaxoSmithKline, and in 2014, Impax Laboratories acquired Core and its affiliated companies for $700 million, subsequently selling Daraprim for $13.50 per pill.

Daraprim remained relatively obscure until Turing Pharmaceuticals secured exclusive distribution rights and dramatically increased the price from $13.50 to $750 per tablet. This price hike rendered the medication unaffordable for many patients and ignited widespread controversy, marking a pivotal moment in pharmaceutical policy. The incident prompted new legislative efforts and heightened scrutiny regarding the exorbitant prices Americans pay for medications.

Although Shkreli faced no legal repercussions for price gouging, he was sentenced to seven years in prison…